A Randomized Pharmacokinetic/Pharmacodynamic Study Comparing the Bioequivalence of Potential Biosimilar Candidate P044 With Reference Medicine in Healthy Volunteers Publisher Pubmed



Raykova E¹ ; Farmahini Farahani M^{2, 3} ; Ivanova S⁴ ; Azhdarzadeh M^{2, 3, 5}
Source: Expert Opinion on Biological Therapy Published:2022

Abstract

Background: P044 is a proposed biosimilar candidate of Teriparatide for reference medicine, Forsteo®. This study was designed to evaluate the Pharmacokinetic/Pharmacodynamic (PK/PD) bioequivalence between P044 and Forsteo®. Methods: In this randomized, open-label, single-dose, crossover study, 66 healthy female subjects were randomized to receive P044 and Forsteo®. The primary PK endpoints of the study were the area under the concentration versus time from zero to infinity (AUC0-inf) and maximum plasma concentration (Cmax). Secondary endpoints included area under the concentration versus time from zero to the last quantifiable concentration (AUC0-last) and Cmax for PD parameter, additional PK parameters and safety. Results: Sixty-six subjects were enrolled in the study and baseline demographics were similar between the two treatments. The two treatments presented similar PK/PD parameters and the 90% confidence interval for primary and secondary endpoints were within the bioequivalence acceptance range (80.00–125.00%) for all parameters. None of the subjects experienced serious adverse event, and all of the reported adverse events were mild and similar between two treatments. Conclusions: This study demonstrated the PK/PD similarity of P044 to reference medicine, Forsteo® and safety profiles were comparable between treatments. Trial Registration: EudraCT Number: 2019–004477-82. © 2021 Informa UK Limited, trading as Taylor & Francis Group.